Downgrading lung nodules at 3-month follow-up 'may be problematic'

A new analysis published in the American Journal of Roentgenology suggests that follow-up imaging protocols for lung nodules identified via CT may need to be revisited. 

The study retrospectively examined the cases of 76 patients who had positive findings (Lung-RADS category ≥3) on their CT lung cancer screening and were eventually diagnosed with cancer. Current Lung-RADS protocols recommend downgrading category 3 or 4 nodules to category 2 if they remain unchanged on imaging for 3 months, citing that a lack of changes indicates the nodules are likely benign. These specific recommendations, however, have many in the radiology community concerned. 

“This guidance may be problematic considering potential slow-growing cancers, such that lack of nodule growth, particularly at short follow-up intervals, may provide false reassurance,” explained study co-authors Suzanne C. Byrne, MD, and Mark M. Hammer, MD, both from the Department of Radiology at Brigham and Women's Hospital in Boston. 
 
During their analysis of the efficacy of completing additional imaging 3 months after LDCT scans uncovered lung nodules, the experts found the protocol to be unreliable. The median time to growth was recorded at 13 and 11 months by linear and volumetric measurements, with a frequency of growth at the 3-month mark of 5% and 7%. 

The authors shared that as the follow-up interval increased, so did nodule growth in many cases, with linear measurements taken at 6 months revealing another 11% of nodules had grown, followed by an additional 10% at 12 months and 6% at 18 months. 

“Growth is slow to manifest by malignant nodules managed by follow-up CT, and a 3-month follow-up CT has very low yield,” the experts shared. “Stability at 3-month follow-up should not provide high confidence in benignity and downgrading all such nodules to category 2 may be problematic.” 

The detailed study abstract can be viewed here

Related lung cancer screening news: 

Q&A: What updated reimbursement policies could mean for CT lung screening rates in the United States

A 'disconcerting' number of patients at high risk of lung cancer put off follow-up care

Lung cancer screenings are proven to save lives, but disparities remain, experts discover

References: 

Malignant Nodules Detected on Lung Cancer Screening CT: Yield of Short-Term Follow-Up CT in Demonstrating Nodule Growth. Suzanne C. Byrne and Mark M. Hammer. American Journal of Roentgenology. 

Hannah murhphy headshot

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She joined Innovate Healthcare in 2021 and has since put her unique expertise to use in her editorial role with Health Imaging.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Trimed Popup
Trimed Popup